Medexprim

Real-Word Evidence
for Better Care

We accelerate personalized medicine in partnership with researchers and innovators.

#mission

One patient,
one disease,
one treatment

A French startup born within a leading University Hospital, Medexprim— acquired by BC Platforms in December 2023— provides software and business intelligence processes to enable collaboration between hospitals and pharmaceutical & Medtech companies. With a core expertise on imaging, Medexprim combines imaging data, clinical data, biology & genomics, to deliver high-quality regulatory-grade multimodal datasets for research.

Hundreds of billions of dollars are invested in clinical research yearly. Only 5% of clinical trials are successful.
Medexprim dramatically reduces the associated time, cost, and risks by digitalizing medical data collection and maximizing its potential for research.

We pioneer new ways
to design and execute clinical trials

We help clinicians, researchers, and innovators to discover and optimize diagnostics, prognostics and treatments for unmet medical needs and better care starting with:

Oncology

Cardiology

Neurology

Rare diseases

#commitments

Advancing clinical research takes a village

That’s why we advocate a partnership approach, working closely with clinicians, researchers and innovators, as well as academic and industrial stakeholders.

Our commitments encompass on-time delivery, unwavering quality, strict compliance, state-of-the-art solutions, and continuous optimization. We are dedicated to exceeding expectations and driving innovation in clinical research.

#Partners

We foster
collaborative partnerships

Medexprim cultivates a network of strategic partners, harnessing collective intelligence to better serve our shared purpose in advancing precision medicine.

#People

A shared governance, fueled by a
collaborative spirit

We’re currently updating this page to provide you with enhanced content.
Please feel free to contact us if you have any questions.

Join a community of
changemakers